文献速递心脑血管急症消化、代谢与肾脏急症

维生素D补充与主要心血管事件:D-Health随机对照试验

Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial.
PubMed 文献 · BMJ · 2023-06-28
一句话结论每月60000 IU维生素D3未能显著降低主要心血管事件(HR 0.91,95%CI 0.81-1.01),心肌梗死风险降低(HR 0.81,95%CI 0.67-0.98)。

D-Health试验在澳大利亚2014至2020年纳入21315名60-84岁老年人,随机接受每月60000 IU维生素D3或安慰剂口服,中位干预5年。主要终点主要心血管事件(心肌梗死、卒中、冠脉血运重建)在维生素D组发生率6.0% vs 安慰剂组6.6%(HR 0.91,95%CI 0.81-1.01),未达统计学显著;心肌梗死风险降低(HR 0.81,95%CI 0.67-0.98),冠脉血运重建(HR 0.89,95%CI 0.78-1.01)和卒中(HR 0.99,95%CI 0.80-1.23)无显著差异。作者认为维生素D可能降低主要心血管事件发生率,但绝对风险差异小且置信区间与无效结果一致。

要点

  • 60-84岁老年人每月口服60000 IU维生素D3 vs 安慰剂,主要心血管事件HR 0.91(95%CI 0.81-1.01),未达统计学显著。
  • 基线正在使用心血管药物者HR 0.84(95%CI 0.74-0.97),但交互作用P=0.12未达显著。
  • 心肌梗死风险降低(HR 0.81,95%CI 0.67-0.98),卒中无差异(HR 0.99,95%CI 0.80-1.23)。
  • 5年标准化病因别累积发生率差异为每1000人-5.8个事件(95%CI -12.2至0.5),避免1例主要心血管事件需治疗172人。

适用人群与场景

  • 澳大利亚2014至2020年纳入的60-84岁老年人,共21315名参与者。
  • 排除标准:自报高钙血症、甲状旁腺功能亢进、肾结石、骨软化症、结节病、每日补充维生素D超过500 IU,或因语言或认知障碍无法签署知情同意者。

处置流程与药物剂量

  • 维生素D组口服维生素D3 60000 IU/月(n=10662),安慰剂组(n=10653),最长干预5年。
  • 完成干预期者:安慰剂组8270人(77.6%),维生素D组8552人(80.2%)。

研究设计与关键结果

  • 随机、双盲、安慰剂对照试验(D-Health试验),采用计算机生成的置换区组随机化分配治疗。
  • 21302人纳入分析,中位干预5年;1336人发生主要心血管事件(安慰剂组699人(6.6%)vs 维生素D组637人(6.0%))。
  • 主要心血管事件发生率维生素D组低于安慰剂组:HR 0.91(95%CI 0.81-1.01);基线正在使用心血管药物者HR 0.84(95%CI 0.74-0.97;交互作用P=0.12),交互作用P值未达显著(<0.05)。
  • 5年标准化病因别累积发生率差异为每1000人-5.8个事件(95%CI -12.2至0.5),避免1例主要心血管事件需治疗172人。
  • 心肌梗死发生率维生素D组低于安慰剂组:HR 0.81(95%CI 0.67-0.98);冠脉血运重建HR 0.89(95%CI 0.78-1.01);卒中无差异:HR 0.99(95%CI 0.80-1.23)。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验。
  • 试验注册号:ACTRN12613000743763。
  • 局限:作者指出绝对风险差异小,且置信区间与无效结果一致。

对床旁实践的改变

  • 作者认为维生素D补充可能降低主要心血管事件发生率,但绝对风险差异小且置信区间与无效结果一致。
  • 作者认为这些发现可推动进一步评估维生素D补充的作用,尤其是在正在使用药物预防或治疗心血管疾病的人群中。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate whether supplementing older adults with monthly doses of vitamin D alters the incidence of major cardiovascular events.

DESIGN: Randomised, double blind, placebo controlled trial of monthly vitamin D (the D-Health Trial). Computer generated permuted block randomisation was used to allocate treatments.

SETTING: Australia from 2014 to 2020.

PARTICIPANTS: 21 315 participants aged 60-84 years at enrolment. Exclusion criteria were self-reported hypercalcaemia, hyperparathyroidism, kidney stones, osteomalacia, sarcoidosis, taking >500 IU/day supplemental vitamin D, or unable to give consent because of language or cognitive impairment.

INTERVENTION: 60 000 IU/month vitamin D3 (n=10 662) or placebo (n=10 653) taken orally for up to five years. 16 882 participants completed the intervention period: placebo 8270 (77.6%); vitamin D 8552 (80.2%).

MAIN OUTCOME MEASURES: The main outcome for this analysis was the occurrence of a major cardiovascular event, including myocardial infarction, stroke, and coronary revascularisation, determined through linkage with administrative datasets. Each event was analysed separately as secondary outcomes. Flexible parametric survival models were used to estimate hazard ratios and 95% confidence intervals.

RESULTS: 21 302 people were included in the analysis. The median intervention period was five years. 1336 participants experienced a major cardiovascular event (placebo 699 (6.6%); vitamin D 637 (6.0%)). The rate of major cardiovascular events was lower in the vitamin D group than in the placebo group (hazard ratio 0.91, 95% confidence interval 0.81 to 1.01), especially among those who were taking cardiovascular drugs at baseline (0.84, 0.74 to 0.97; P for interaction=0.12), although the P value for interaction was not significant (<0.05). Overall, the difference in standardised cause specific cumulative incidence at five years was -5.8 events per 1000 participants (95% confidence interval -12.2 to 0.5 per 1000 participants), resulting in a number needed to treat to avoid one major cardiovascular event of 172. The rate of myocardial infarction (hazard ratio 0.81, 95% confidence interval 0.67 to 0.98) and coronary revascularisation (0.89, 0.78 to 1.01) was lower in the vitamin D group, but there was no difference in the rate of stroke (0.99, 0.80 to 1.23).

CONCLUSIONS: Vitamin D supplementation might reduce the incidence of major cardiovascular events, although the absolute risk difference was small and the confidence interval was consistent with a null finding. These findings could prompt further evaluation of the role of vitamin D supplementation, particularly in people taking drugs for prevention or treatment of cardiovascular disease.

TRIAL REGISTRATION: ACTRN12613000743763.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Thompson B, Waterhouse M, English DR, et al. Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial. BMJ. 2023. PMID: 37380191. doi:10.1136/bmj-2023-075230

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。